Neonatal jaundice. Neonatal jaundice due to other excessive haemolysis, Neonatal jaundice from other and unspecified causes
Conditions
Interventions
Intervention 1: Intervention Group: Phototherapy (with 8-lamp Phototherapy unit made by Tousan Company
Tehran, Iran) along with 10 mg/kg/day divided q12h ursodeoxycholic acid (made by Dr. Adidbi Company
Tehran, Iran).
The intervention for each patient will start since him/her hospitalization and will continue until him/her total bilirubin level reaches below 10mg/dL. Intervention 2: Control Group: Ph
Tehran, Iran) along with water as placebo.
The intervention for each patient will start since him/her hospitalization and will continue until him/her total bilirubin level reaches below 10mg/dL.
Treatment - Drugs
Placebo
Intervention Group: Phototherapy (with 8-lamp Phototherapy unit made by Tousan Company
Tehran, Iran).
The intervention for each patient will start since him/her hospitalization and will continue until him/her total bilirubin level reaches below 10mg/dL.
Control Group: Phototherapy (with 8-lamp Phototherapy unit made by Tousan Company
Tehran, Iran) along with water as placebo.
The intervention for each patient will start since him/her hospitalization and will continue until him/her total bilirubin level reaches below 10mg/dL.
Sponsors
Vice chancellor for research, Ardabil University of Medical Sciences
Eligibility
Sex/Gender
All
Age
3 Days to 28 Days
Inclusion criteria
Inclusion criteria: Inclusion criteria: Birth weight between 2500 to 4000 g; Only breastfeeding; Gestational age between 38 to 41 weeks; Older than 3 days, total bilirubin between 14 to 20 mg/dL; direct bilirubin less than 2 mg/dL. Exclusion criteria: ABO and RH incompatibility; G6PD Deficiency; Direct hyperbilirubinemia; Septicemia; diseases leading to hyperbilirubinemia (including Crigler-Najjar syndrome, Gilbert's syndrome, hypothyroidism / hyperthyroidism, liver diseases, and ....); Premature infants; Newborns of diabetic mothers.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total bilirubin. Timepoint: on admission and every 12 hours after admission until discharge. Method of measurement: Blood sampling.;Time duration in which bilirubin levels reaches to normal level. Timepoint: Continuously (from treatment beginning until bilirubin reach to normal levels). Method of measurement: Timer. | — |
Secondary
| Measure | Time frame |
|---|---|
| -. Timepoint: -. Method of measurement: -. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactShima Sarfarazi
Ardabil University of Medical Sciences
Outcome results
None listed